Dopamine D3 receptor antagonists in pathologic gambling


Presents a study which aims to examine the role played by dopamine D3 receptor antagonists pathologic gambling. Specifically the study assessed the efficacy and safety of ABT-925 in the treatment of patients with acute exacerbation of schizophrenia. One hundred fifty five patients were evaluated over a 6-week period, and the primary efficacy measure was mean change from baseline to final evaluation on the Positive and Negative Syndrome Scale total score. No statistically significant treatment effect was observed with ABT-925 50 mg/d or 150 mg/d compared with placebo on primary or secondary efficacy end points. ABT-925 50 mg/d and 150 mg/d were generally well tolerated, with adverse event profiles similar to that of placebo. The ideal clinical setting for testing the efficacy of ABT-925 in patients with pathologic gambling is a double- blind, placebo-controlled assay with a measurement of the percentage of D3 receptors blockade in the nucleus accumbens of patients receiving ABT-925 using positron emission tomography scans. (PsycINFO Database Record (c) 2013 APA, all rights reserved)

Problem with this document? Please report it to us.